Literature DB >> 18973964

ADMA, cardiovascular disease and diabetes.

Katarzyna Krzyzanowska1, Friedrich Mittermayer, Michael Wolzt, Guntram Schernthaner.   

Abstract

The endogenous competitive nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is an emerging risk marker for future cardiovascular events. Elevated ADMA concentrations have been described in patients with an adverse cardiovascular risk profile. Recently, various studies investigated the independent role of ADMA as a cardiovascular risk predictor in several patient cohorts. In addition, ADMA might not only be a risk marker but also a causative factor for cardiovascular disease. This review summarizes the literature on the relationship between ADMA, cardiovascular disease and diabetes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18973964     DOI： 10.1016/j.diabres.2008.09.024

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  12 in total

Review 1.  Small Molecule Inhibitors of Protein Arginine Methyltransferases.

Authors:  Hao Hu; Kun Qian; Meng-Chiao Ho; Y George Zheng
Journal:  Expert Opin Investig Drugs       Date:  2016-02-16       Impact factor: 6.206

2.  Chitotriosidase activity predicts endothelial dysfunction in type-2 diabetes mellitus.

Authors:  Alper Sonmez; Cem Haymana; Serkan Tapan; Umut Safer; Gurkan Celebi; Ozlem Ozturk; Halil Genc; Teoman Dogru; Ilker Tasci; Gokhan Erdem; Abdullah Taslipinar; Aydogan Aydogdu; Mahmut I Yilmaz; Ismail Kurt; Mustafa Kutlu
Journal:  Endocrine       Date:  2010-04-11       Impact factor: 3.633

3.  Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?

Authors:  Antonio Aversa; Roberto Bruzziches; Davide Francomano; Marco Natali; Andrea Lenzi
Journal:  Ther Adv Urol       Date:  2009-10

4.  Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus.

Authors:  Sema Uslu; Nur Kebapçi; Mehmet Kara; Cengiz Bal
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

5.  Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine.

Authors:  Ahmed M Mohamadin; Fawzia A Habib; Abdulrahman A Al-Saggaf
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

6.  A Prospective Analysis of Circulating Plasma Metabolites Associated with Ovarian Cancer Risk.

Authors:  Clary B Clish; Shelley S Tworoger; Oana A Zeleznik; A Heather Eliassen; Peter Kraft; Elizabeth M Poole; Bernard A Rosner; Sarah Jeanfavre; Amy A Deik; Kevin Bullock; Daniel S Hitchcock; Julian Avila-Pacheco
Journal:  Cancer Res       Date:  2020-01-22       Impact factor: 12.701

7.  Asymmetric dimethylarginine and carotid atherosclerosis in Type 2 diabetes mellitus.

Authors:  W Xia; Y Shao; Y Wang; X Wang; Y Chi
Journal:  J Endocrinol Invest       Date:  2012-10       Impact factor: 4.256

8.  ADMA (asymmetric dimethylarginine) and angiogenic potential in patients with type 2 diabetes and prediabetes.

Authors:  Radosław Wieczór; Anna M Wieczór; Arleta Kulwas; Danuta Rość
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-22

9.  Cardiovascular Risk in Women With PCOS.

Authors:  Pietro Scicchitano; Ilaria Dentamaro; Rosa Carbonara; Gabriella Bulzis; Annamaria Dachille; Paola Caputo; Roberta Riccardi; Manuela Locorotondo; Cosimo Mandurino; Marco Matteo Ciccone
Journal:  Int J Endocrinol Metab       Date:  2012-09-30

10.  Effect of resistance training on plasma nitric oxide and asymmetric dimethylarginine concentrations in type I diabetic rats.

Authors:  Parivash Shekarchizadeh Esfahani; Reza Gharakhanlou; Jahangir Karimian; Majid Khazaei; Awat Feizi; Alireza Safarzade
Journal:  Int J Prev Med       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.